Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LavipharmFRA:BXA0 +0.78%79 Dividend Payout Ratio is 1.00 as of Dec. 2025, which is 41% above its 10-year median of 0.71. GuruFocus rates FRA:BXA0 with a GF Score™ of 79/100 and a GF Value™ of €1.03 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 445 Drug Manufacturers companies, Lavipharm ranks worse than 81.35% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Lavipharm's Dividend Payout Ratio for the
months ended in Dec. 2025 was 1.00.
The historical rank and industry rank for Lavipharm's Dividend Payout Ratio or its related term are showing as below:
FRA:BXA0'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.69 Med: 0.71 Max: 0.71
Current: 0.69
During the past 9 years, the highest Dividend Payout Ratio of Lavipharm was 0.71. The lowest was 0.69. And the median was 0.71.
FRA:BXA0's Dividend Payout Ratio is ranked worse than 81.35% of 445
companies
in the Drug Manufacturers industry
Industry Median: 0.38
vs FRA:BXA0: 0.69
Lavipharm (FRA:BXA0) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Lavipharm Dividend Payout Ratio Related Terms
Lavipharm Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Lavipharm's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BXA0 vs ZTS, UTHR, VTRS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lavipharm Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lavipharm's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Lavipharm's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Lavipharm's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lavipharm (FRA:BXA0) has a Dividend Payout Ratio of 1.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Lavipharm and its competitors. This is 41% above median its historical median of 0.71. Over the past decade, Lavipharm's Dividend Payout Ratio has ranged from 0.69 to 0.71. According to the industry distribution chart, Lavipharm ranks #362 out of 445 companies in the Drug Manufacturers industry, placing it in the top 81.3%.
Is Lavipharm's Dividend Payout Ratio too high?
Lavipharm's current Dividend Payout Ratio of 1.00 is 41% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 0.71. The Drug Manufacturers industry median Dividend Payout Ratio is 0.38. Lavipharm's value of 1.00 is 163.2% above this industry median. Based on the distribution chart, Lavipharm ranks #362 out of 445 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lavipharm has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lavipharm ranks #362 out of 445 companies for Dividend Payout Ratio. This places Lavipharm in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. Lavipharm's value of 1.00 is 163.2% above this benchmark. Historically, Lavipharm's own Dividend Payout Ratio has ranged from 0.69 to 0.71 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.38, Lavipharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lavipharm's current Dividend Payout Ratio of 1.00 is 163.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Lavipharm and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lavipharm's current Dividend Payout Ratio is 1.00, which is 41% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (FRA:BXA0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.03, compared to a current price of €1.55 — trading 50.5% above its estimated fair value. The current Dividend Payout Ratio is 1.00, which is 41% above median its 10-year median of 0.71 and 163.2% above the Drug Manufacturers industry median of 0.38. Lavipharm's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Lavipharm (FRA:BXA0), the current Dividend Payout Ratio is 1.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lavipharm (FRA:BXA0) Overvalued in 2026?
Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued.
The current stock price of €1.55 is trading 50.5% above its estimated GF Value™ of €1.03.
GuruFocus considers Lavipharm to be Significantly Overvalued.
Key valuation signals for FRA:BXA0:
Dividend Payout Ratio: 1.00 (41% above median its 10-year median of 0.71)
GF Value™: €1.03 vs. price of €1.55 (50.5% above fair value)
Industry Position: 163.2% above the Drug Manufacturers median (#362 of 445)
No single metric tells the full story. See the FRA:BXA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
79GF Score
Get the complete analysis for FRA:BXA0
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BXA0 has been successfully added to your 
